RWE and Patient-Centered Outcomes
Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. When that evidence reflects patient outcomes, it provides an invaluable perspective on the consumer experience. Explore our real-world evidence (RWE) analyses and guidance to support your strategic decisions.
Video: Inside Compendia: Off-Label Applications
Avalere Health Advisory experts discuss how compendium shape off-label drug use, underscoring both benefits and risks in clinical decision-making.
EHDS Aims to Transform Data Access Across EU Health Systems
The European Health Data Space aims to enable secure, unified health data access across Europe, supporting research, innovation, and improved patient outcomes.
Video: Inside Compendia: Expanding Intended Use Populations
In the second installment of our Inside Compendia series, Avalere Health Advisory experts discuss how compendia can support clinical decision-making and medication access, highlighting a case study on GLP-1s.
Strategic Entry Points for Shaping USPSTF Recommendations
Avalere Health helps innovators shape USPSTF recommendations, driving preventive care access, payer coverage, and clinical adoption.
White Paper: Estimated Federal Savings from the Special Diabetes Program
Avalere Health finds that research funded by the Special Diabetes Program has yielded more than $50 billion in federal healthcare savings
White Paper: The Cost of Opioid Use Disorder
Avalere Health finds opioid use disorder costs businesses, governments, and households almost $1 trillion per year, but treatment with medications can lower costs.
RWE Data Management Lessons Applicable to NIH Autism Database
The NIH recently announced plans to develop an RWE database to study autism spectrum disorders. In doing so, they can learn lessons encountered by life sciences companies developing data ecosystems for their products.
Manufacturers Must Adapt to Growing GLP-1 and GIP/GLP-1 RA Markets
As the GLP-1 product market continues to expand, manufacturers must find ways to differentiate their inline and pipeline assets with new evidence and strong value story.
National Kidney Month: Setting the Stage for 2025 Changes
Political changes, transplant system reforms, research advancements, and expanded CKD indications create opportunities and challenges in the kidney care space.
Disease Registries Offer Solutions in Rare Disease
Disease registries can provide high-quality data and may serve as an additional resource when developing medical interventions for rare and ultra-rare diseases.
Telehealth in Medicare: Shifts Before and After COVID-19
Pandemic-era telehealth flexibilities in Medicare will expire in April 2025, potentially limiting primary care access for beneficiaries.
Stakeholders Can Influence Patient-Centered Value Research During Public Comment Period
Life sciences companies, payers, and advocates can weigh in on patient-centered value assessments in a new public comment opportunity.
Opportunities to Move the Needle on US Behavioral Healthcare in 2025
Behavioral health is at a turning point in 2025, with newly implemented policies, groundbreaking treatments, and novel regulatory and financial dynamics.
eBook: Rare Disease Biotechnology Landscape, 2025
In an eBook, Avalere Health experts describe the policy, market access, and evidence landscape of rare disease in the United States and globally.
Evidence Generation and Access at the San Antonio Breast Cancer Symposium
At a breast cancer symposium, Avalere oncology advisory experts connected with colleagues to discuss early detection, precision medicine, and clinical trials.
NORD Summit Reveals 2025 Rare Disease Priorities
Avalere attendees of the National Organization of Rare Disorders (NORD) Breakthrough Summit shared a recap of themes from the conference in MedAd News.
Avalere Published in PM360: Research that Reflects Reality
For researchers developing new medicines and therapies, real-world data gives them an understanding of patients’ actual experiences outside of clinical trials.
Rethinking Evidence Strategy in HEOR Budget Planning
Avalere experts in health economics and outcomes research (HEOR) identify four elements of evidence strategy development in Pharma Focus America.
Updated Negotiation ICR Presents New Industry Evidence Needs
Updates in the Initial IPAY 2027 ICR highlight the increasing needs for specific evidence planning and generation for industry to prepare for negotiation.
Rethink Evidence Strategy this HEOR Budget Planning Season
Budgeting season offers HEOR teams the opportunity to revisit research and evidence needs and update their commercialization strategy based on market dynamics.